Quick Comparison
| NMN (Nicotinamide Mononucleotide) | Noopept | |
|---|---|---|
| Half-Life | 2-3 minutes in blood (rapidly converted to NAD+). NAD+ half-life: 1-2 hours in tissue | 30-60 minutes (active metabolite cycloprolylglycine persists longer) |
| Typical Dosage | Standard: 250-1000 mg daily. Sublingual may improve bioavailability by bypassing first-pass metabolism. Take in the morning — NAD+ follows circadian rhythm and morning supplementation aligns with natural peaks. Effects build over weeks. | Standard: 10-30 mg sublingually or orally, 2-3 times daily. Sublingual administration provides faster onset. Do not exceed 30 mg per dose. |
| Administration | Oral (capsules, powder, sublingual). Sublingual may improve bioavailability. Store in cool, dry place. | Oral or sublingual (sublingual preferred for faster onset and higher bioavailability). Available as powder, capsules, or sublingual tablets. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
NMN (Nicotinamide Mononucleotide)
NMN is transported into cells via the Slc12a8 transporter (highly expressed in the small intestine and brain) and converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1 in the nucleus, NMNAT2 in axons/Golgi, NMNAT3 in mitochondria). Elevated NAD+ activates the sirtuin family of NAD+-dependent protein deacetylases: SIRT1 deacetylates PGC-1alpha to promote mitochondrial biogenesis, SIRT3 activates superoxide dismutase 2 (SOD2) and isocitrate dehydrogenase 2 (IDH2) for mitochondrial antioxidant defense, and SIRT6 promotes base excision repair of oxidative DNA damage. NAD+ is also consumed by poly(ADP-ribose) polymerases (PARP1/2) during DNA repair — age-related NAD+ depletion impairs PARP function, allowing DNA damage accumulation. In neurons, NAD+ is required for glycolysis (GAPDH cofactor), the TCA cycle, and Complex I of the electron transport chain, directly fueling the enormous ATP demands of synaptic transmission. NAD+ decline with aging (approximately 50% reduction between ages 40-60) reduces all of these processes simultaneously, creating a cascade of mitochondrial dysfunction, impaired DNA repair, and neuroinflammation that NMN supplementation aims to reverse.
Noopept
Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.
Risks & Safety
NMN (Nicotinamide Mononucleotide)
Common
Mild flushing, nausea, headache initially.
Serious
Long-term human safety data still limited (first human trials completed 2020-2023). Theoretical concern about promoting cancer growth in existing tumors (NAD+ fuels fast-growing cells).
Rare
Insomnia if taken late.
Noopept
Common
Headache (especially without choline supplementation), irritability at higher doses, brain fog in some users.
Serious
No serious adverse effects documented.
Rare
Emotional blunting at high doses, insomnia, allergic reactions.
Full Profiles
NMN (Nicotinamide Mononucleotide) →
A direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme essential for cellular energy production, DNA repair, and sirtuin activation. NAD+ levels decline 50% between ages 40 and 60, contributing to age-related cognitive decline and neurodegeneration. NMN supplementation restores NAD+ levels and improves mitochondrial function, memory, and neuroplasticity in animal models.
Noopept →
A synthetic peptide-derived nootropic often grouped with racetams due to similar effects, though it is technically a dipeptide analog of piracetam. Roughly 1000x more potent by weight than piracetam, requiring only 10-30 mg per dose. It provides both immediate cognitive enhancement and long-term neuroprotective benefits through BDNF and NGF upregulation.